Century Therapeutics, Inc.
IPSC
$0.5216
-$0.0002-0.04%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 4.17M | 791.00K | 771.00K | 855.00K | 268.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.17M | 791.00K | 771.00K | 855.00K | 268.00K |
| Cost of Revenue | 29.38M | 27.23M | 27.22M | 23.42M | 22.30M |
| Gross Profit | -25.20M | -26.44M | -26.45M | -22.57M | -22.03M |
| SG&A Expenses | 9.11M | 8.35M | 8.31M | 8.74M | 8.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.49M | 35.58M | 35.53M | 32.16M | 30.89M |
| Operating Income | -34.31M | -34.79M | -34.76M | -31.31M | -30.62M |
| Income Before Tax | -34.30M | -31.23M | -31.19M | -28.06M | -40.27M |
| Income Tax Expenses | 1.78M | -8.00K | 22.00K | 1.00K | -869.00K |
| Earnings from Continuing Operations | -36.07M | -31.23M | -31.21M | -28.06M | -39.40M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.07M | -31.23M | -31.21M | -28.06M | -39.40M |
| EBIT | -34.31M | -34.79M | -34.76M | -31.31M | -30.62M |
| EBITDA | -31.00M | -31.49M | -31.29M | -28.08M | -27.07M |
| EPS Basic | -0.42 | -0.37 | -0.38 | -0.45 | -0.66 |
| Normalized Basic EPS | -0.23 | -0.23 | -0.24 | -0.28 | -0.28 |
| EPS Diluted | -0.42 | -0.37 | -0.38 | -0.45 | -0.66 |
| Normalized Diluted EPS | -0.23 | -0.23 | -0.24 | -0.28 | -0.28 |
| Average Basic Shares Outstanding | 85.41M | 84.70M | 82.09M | 62.30M | 60.00M |
| Average Diluted Shares Outstanding | 85.41M | 84.70M | 82.09M | 62.30M | 60.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |